Table 2 Pharmacokinetic properties of IgG variants.
From: Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
Variant | t1/2* (d) | Cmax* (μg/mL) | Clast* (μg/mL) | AUClast (day*μg/mL) | AUC∞ (day*μg/mL) |
|---|---|---|---|---|---|
anti-human RSV | 7.2 ± 4.0 | 35.0 ± 3.4 | 1.6 ± 1.4 | 117.0 ± 43.6 | 138.4 ± 61.9 |
anti-gp120 | 8.9 ± 2.9 | 46.2 ± 23.4 | 3.0 ± 1.1 | 195.3 ± 9.7 | 233.7 ± 21.2 |
anti-RSV I253D | 9.7 ± 2.9 | 39.5 ± 8.2 | 0.04 ± 0.02 | 34.6 ± 8.3 | 35.2 ± 8.4 |
anti-RSV Q311R | 7.1 ± 3.0 | 47.8 ± 21.9 | 2.2 ± 2.4 | 153.1 ± 65.0 | 182.6 ± 102.3 |
anti-RSV Q311R x anti-gp120 | 11.7 ± 1.8 | 53.2 ± 26.9 | 5.4 ± 0.8 | 259.2 ± 13.2 | 351.3 ± 14.5 |
anti-RSV T307P, L309Q, Q311R | 8.9 ± 4.3 | 59.9 ± 18.4 | 3.2 ± 2.4 | 180.1 ± 42.1 | 231.3 ± 96.8 |
anti-RSV T307P, L309Q, Q311R x anti-gp120 | 7.7 ± 3.3 | 34.2 ± 4.5 | 1.4 ± 1.4 | 138.2 ± 18.6 | 158.4 ± 22.6 |
anti-RSV H435R | 12.1 ± 3.7 | 17.8 ± 2.5 | 1.6 ± 0.8 | 189.9 ± 44.8 | 220.1 ± 56.4 |
anti-RSV H435R, Y436F | 13.0 ± 3.2 | 17.1 ± 6.6 | 1.5 ± 0.6 | 181.9 ± 42.1 | 211.6 ± 56.4 |
